03-06-2024 / Dr. Paul Maciocia, Clinical Scientist and Honorary Consultant Haematologist, Cancer Institute, University College London
Discover a groundbreaking webinar exploring the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL).
Learn More
11-07-2023 / Dr. Kevin Chen, Director of mRNA & Plasmid
The approval of messenger RNA (mRNA)-based COVID-19 vaccines marked a scientific turning point, establishing mRNA as a novel drug modality with significant therapeutic potential. However, linear mRNAs have a short half-life and require base modifications
Learn More
10-07-2020 / Marvin Gee, Ph.D. Co-Founder and Head of Target Discovery
Target identification in solid tumors can help enable therapeutic development against indications of high unmet need and across a wide patient population.
Learn More
09-30-2020 / Grace Tan, Ph.D. Product Manager, GenScript Reagent Antibody Services
The SARS-CoV-2 pandemic necessitated the rapid development of high-quality monoclonal antibodies (mAbs) for therapeutic, diagnostic, and vaccine development.
Learn More
09-10-2020 / Raymond Miller, Ph.D., GenScript. Julie Rumble Ph.D., Cayman Chemical
Neoantigen based immuno-oncology therapies are proving promising, but neoantigen identification and production are bottlenecks to boosting efficacy.
Learn More
08-28-2020 / Dr. Pei Liu, Senior Scientist, Antibody Department, GenScript
The COVID-19 pandemic has caused great devastation throughout the world, and effective solutions to clinically detect the virus are urgently needed. While the qRT-PCR method is useful for detecting the presence of SARS-CoV-2 virus in people, it is useful
Learn More
08-06-2020 / Vevian Zhang, Product Manager, GenScript
Inhibitors of immune-checkpoint proteins, such as PD1, PD-L1, VISTA, Tim3 and Lag3, have indicated broad and diverse opportunities to increase antitumor immunity by enhancing T cell activity with the potential to produce durable clinical responses.
Learn More
05-18-2020 / Casey Maguire, Ph.D.
Gene therapy to treat human disease has evolved from a relatively small group of dedicated scientists working on the fundamentals of gene delivery to mammalian cells, to a large industry capable of ex-vivo and in vivo gene therapy in patients.
Learn More